The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index; 29 of the 47 sources its claims cite were checked for support.
Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene
Open accessAbstract
BACKGROUND: Genetic diversity of mutations in the CYP21A2 gene is the main cause of the monogenic congenital adrenal hyperplasia (CAH) disorder. On chromosome 6p21.3, the CYP21A2 gene is partially overlapped by the TNXB gene, the two residing in tandem with their highly homologous corresponding pseudogenes (CYP21A1P and TNXA), which leads to recurrent homologous recombination. METHODS AND RESULTS: In the present study, the genetic status of an ethnic Greek-Cypriot family, with a female neonate that was originally classified as male and manifested the salt-wasting (SW) form, is presented. Genetic defects in the CYP21A2 and TNXB genes were investigated by Sanger sequencing multiplex ligation-dependent probe amplification (MLPA) and a real-time PCR assay. The neonate carried in compound heterozygosity the TNXA/TNXB chimeric gene complex (termed CAH-X CH-1) that results in a contiguous CYP21A2 and TNXB deletion and in her second allele the pathogenic IVS2-13A/C > G (c.655A/C > G) in CYP21A2. CONCLUSIONS: The classic SW-CAH due to 21-hydroxylase (21-OH) deficiency may result from various complex etiological mechanisms and, as such, can involve the formation of monoallelic TNXA/TNXB chimeras found in trans with other CYP21A2 pathogenic variants. This is a rare case of CAH due to 21-hydroxylase deficiency, which elucidates the role of the complex RCCX CNV structure in the development of the disease. Identification of the correct CAH genotypes for a given phenotype is of considerable value in assisting clinicians in prenatal diagnosis, appropriate treatment, and genetic counseling.
Overview
CoChat Summary
## TL;DR
This paper reports a rare salt-wasting classic congenital adrenal hyperplasia (SW-CAH) case in a Greek-Cypriot neonate caused by compound heterozygosity for a TNXA/TNXB chimera (CAH-X CH-1) and the pathogenic CYP21A2 variant IVS2-13A/C > G. The case illustrates how complex RCCX copy-number variation can shape CAH phenotype and why detailed genotyping matters for diagnosis, treatment, and counseling.
## Key findings
- The neonate had SW-CAH with severe virilization (Prader 5) and biochemical salt-wasting findings, including hyponatremia, hyperkalemia, high plasma renin activity, 17-OHP > 75.7 nmol/L, and high ACTH.
- Genetic testing by Sanger sequencing, MLPA, and real-time PCR showed the infant was compound heterozygous for CAH-X CH-1 and IVS2-13A/C > G (c.655A/C > G) in CYP21A2.
- The mother carried IVS2-13A/C > G in heterozygosity, and the father carried the TNXA/TNXB chimera (CAH-X CH-1) in heterozygosity.
- The authors note that CAH-X syndrome is estimated in ~7–9% of CAH patients, and ~10% of classic SW-CAH patients harboring a TNXB/CYP21A2 genotype may show the extended CAH-X phenotype.
## Methods
- Design: Single-patient family case study with molecular characterization of a classic SW-CAH presentation.
- Sample/data: A female neonate from a non-consanguineous Greek-Cypriot family, plus both parents; clinical history and biochemical findings were used alongside DNA testing.
- Analysis: Sanger sequencing, MLPA, and a real-time PCR CAH Real Fast CNV assay were used to investigate CYP21A2 and TNXB defects and confirm the large deletion/chimeric allele.
## Limitations
- The paper states no formal study limitations; this is a single rare case report, so the findings are inherently not generalizable beyond this family.
- The text makes evident that no long-term follow-up or broader phenotype assessment (for example, later CAH-X/EDS manifestations) is reported here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
17 Valid · 3 Not valid · 2 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Several other studies that followed have reported an incidence of IVS2-13A/C > G combined with the chimeric TNXA/TNXB (CAH-X CH-1) genotype in patients with 21-OH deficiency and with no EDS manifestations [32, 44].”
§ Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene > Discussion CAH-X syndrome is estimated to be found in approximately 7–9% of CAH patients [7, 14, 34] and is classified into three types (CAH-X CH-1, CAH-X CH-2, and CAH-X CH-3) as a result of chimeric recombination events between the TNXB/TNXA during meiosis, resulting in the deletion of the CYP21A2 gene [15]. The CAH-X CH-1 type is the most frequent of the three and retains a 120-bp deletion at the boundary of exon 35 and intron 35 of TNXB. CAH-X CH-2 and CAH-X CH-3 types are less frequently found in CAH patients, with CAH-X CH-2 being characterized by the variant c.12174C > G (p.Cys4058Trp), which derives from the TNXA pseudogene [7], and CAH-X CH-3, being characterized by a cluster of three mutations (p.Arg4073His, p.Asp4172Asn, and p.Ser4175Asn) also derived from the TNXA pseudogene [35]. CAH-X CH-1 does not produce structural changes in the TNX protein but, rather, reduces the TNX expression, this being in contrast to the altered production of TNX proteins from both CAH-X CH-2 and CAH-X CH-3 [35]. An in-depth molecular genetic approach for the correct diagnosis of the severe forms of CAH, including CAH-X syndrome, is absolutely essential and indeed makes a difference to the everyday practice of an experienced endocrinologist. Lately, in addition to Sanger analysis, which still remains the gold standard for the detection of CYP21A2 gene mutations, the PCR-based techniques of MLPA and real-time PCR assays are widely used for the detection of the severe deletions or duplications. Therefore, in the endocrinologist’s everyday practice, genetic information obtained by using these techniques aids towards taking the most appropriate decisions in cases of prenatal and preimplantation genetic diagnosis, hormonal treatment, and genetic counseling. The female neonate with the classic SW-CAH of the present study presented the highest degree of virilization, with an external genital appearance of Prader 5, and, when salt supplementation was stopped at the age of 4 months, she underwent surgery for the correction of the appearance of her genitalia where a vaginal opening was formed. Similarly to the neonate of the present study, CAH patients that carry in compound heterozygosity the splice IVS2-13A/C > G with the TNXA/TNXB (CAH-X CH-1) chimera generally have the most severe SW phenotype [36–38]. Several reports in European, Mediterranean, Middle Eastern, and Chinese populations confirmed a high frequency of the pathogenic IVS2-13A/C > G and found it to comprise 20 to 25% of the CYP21A2 mutant alleles and to translate to the most severe SW forms of the disease when inherited in homozygosity [1, 4, 27, 39–43]. Since the first CAH-X syndrome report by Merke et al. [14], it has been established that only 10% of CAH-X patients also have EDS manifestations [15, 44]. Several other studies that followed have reported an incidence of IVS2-13A/C > G combined with the chimeric TNXA/TNXB (CAH-X CH-1) genotype in patients with 21-OH deficiency and with no EDS manifestations [32, 44]. Similarly, the neonate of the present case with a compound heterozygous IVS2-13A/C > G/CAH-X CH-1 genotype presented only SW 21-hyroxylase deficiency and no EDS-related clinical manifestations. More specifically, our case has normal skin when compared to certain patients with biallelic CAH-X genotype and who typically demonstrate skin laxity and abnormal wound healing [45, 46]. The father of the neonate who was a carrier of the chimeric TNXA/TNXB (CAH-X CH-1) genotype also did not present any clinical manifestations of EDS. In conclusion, we herein report an infrequent case of CAH illustrating that its clinical phenotype depends on the severity of the underlying variants, while the role of the complex RCCX CNV structure in the development of the disease is explained. Our report moreover constitutes an example of the complexities encountered in patients with classic CAH and adds to the understanding of the spectrum of CAH phenotype and the TNX-related disorders, including the CAH-X syndrome.
What the sources say
- Not checked — no full text of the sourcecites [32] Gao Y, Lu L, Yu B, Mao J, Wang X, Nie M, Wu X (2020) The prevalence of the chimeric TNXA/TNXB gene and clinical symptoms of Ehlers-Danlos syndrome with 21-hydroxylase deficiency. J Clin Endocrinol Metab 105(7):2288. https://doi.org/10.1210/clinem/dgaa199 source
- Disputedcites [44] Marino R, Garrido NP, Ramirez P, Notaristefano G, Moresco A, Touzon MS, Vaiani E, Finkielstain G, Obregon MG, Balbi V, Soria I, Belgorosky A (2021) Ehlers-Danlos syndrome: molecular and clinical characterization of TNXA/TNXB chimeras in congenital adrenal hyperplasia. J Clin Endocrinol Metab 106(7):e2789–e2802. https://doi.org/10.1210/clinem/dgab033 sourceExperimental — accuracy not yet measured
The Molecular Analysis table lists patients with an “In2” variant and CH1, but does not establish that these patients lacked EDS manifestations. The Clinical Findings section says all evaluated probands had features of the hEDS phenotype, and the Discussion says EDS features were found in every patient available for clinical evaluation. Patients who were not evaluated cannot be counted as having no manifestations. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly to the neonate of the present study, CAH patients that carry in compound heterozygosity the splice IVS2-13A/C > G with the TNXA/TNXB (CAH-X CH-1) chimera generally have the most severe SW phenotype [36–38].”
§ Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene > Discussion CAH-X syndrome is estimated to be found in approximately 7–9% of CAH patients [7, 14, 34] and is classified into three types (CAH-X CH-1, CAH-X CH-2, and CAH-X CH-3) as a result of chimeric recombination events between the TNXB/TNXA during meiosis, resulting in the deletion of the CYP21A2 gene [15]. The CAH-X CH-1 type is the most frequent of the three and retains a 120-bp deletion at the boundary of exon 35 and intron 35 of TNXB. CAH-X CH-2 and CAH-X CH-3 types are less frequently found in CAH patients, with CAH-X CH-2 being characterized by the variant c.12174C > G (p.Cys4058Trp), which derives from the TNXA pseudogene [7], and CAH-X CH-3, being characterized by a cluster of three mutations (p.Arg4073His, p.Asp4172Asn, and p.Ser4175Asn) also derived from the TNXA pseudogene [35]. CAH-X CH-1 does not produce structural changes in the TNX protein but, rather, reduces the TNX expression, this being in contrast to the altered production of TNX proteins from both CAH-X CH-2 and CAH-X CH-3 [35]. An in-depth molecular genetic approach for the correct diagnosis of the severe forms of CAH, including CAH-X syndrome, is absolutely essential and indeed makes a difference to the everyday practice of an experienced endocrinologist. Lately, in addition to Sanger analysis, which still remains the gold standard for the detection of CYP21A2 gene mutations, the PCR-based techniques of MLPA and real-time PCR assays are widely used for the detection of the severe deletions or duplications. Therefore, in the endocrinologist’s everyday practice, genetic information obtained by using these techniques aids towards taking the most appropriate decisions in cases of prenatal and preimplantation genetic diagnosis, hormonal treatment, and genetic counseling. The female neonate with the classic SW-CAH of the present study presented the highest degree of virilization, with an external genital appearance of Prader 5, and, when salt supplementation was stopped at the age of 4 months, she underwent surgery for the correction of the appearance of her genitalia where a vaginal opening was formed. Similarly to the neonate of the present study, CAH patients that carry in compound heterozygosity the splice IVS2-13A/C > G with the TNXA/TNXB (CAH-X CH-1) chimera generally have the most severe SW phenotype [36–38]. Several reports in European, Mediterranean, Middle Eastern, and Chinese populations confirmed a high frequency of the pathogenic IVS2-13A/C > G and found it to comprise 20 to 25% of the CYP21A2 mutant alleles and to translate to the most severe SW forms of the disease when inherited in homozygosity [1, 4, 27, 39–43]. Since the first CAH-X syndrome report by Merke et al. [14], it has been established that only 10% of CAH-X patients also have EDS manifestations [15, 44]. Several other studies that followed have reported an incidence of IVS2-13A/C > G combined with the chimeric TNXA/TNXB (CAH-X CH-1) genotype in patients with 21-OH deficiency and with no EDS manifestations [32, 44]. Similarly, the neonate of the present case with a compound heterozygous IVS2-13A/C > G/CAH-X CH-1 genotype presented only SW 21-hyroxylase deficiency and no EDS-related clinical manifestations. More specifically, our case has normal skin when compared to certain patients with biallelic CAH-X genotype and who typically demonstrate skin laxity and abnormal wound healing [45, 46]. The father of the neonate who was a carrier of the chimeric TNXA/TNXB (CAH-X CH-1) genotype also did not present any clinical manifestations of EDS. In conclusion, we herein report an infrequent case of CAH illustrating that its clinical phenotype depends on the severity of the underlying variants, while the role of the complex RCCX CNV structure in the development of the disease is explained. Our report moreover constitutes an example of the complexities encountered in patients with classic CAH and adds to the understanding of the spectrum of CAH phenotype and the TNX-related disorders, including the CAH-X syndrome.
What the sources say
- Not checked — no full text of the sourcecites [36] Lee HH (2005) Chimeric CYP21P/CYP21 and TNXA/TNXB genes in the RCCX module. Mol Genet Metab 84(1):4–8. https://doi.org/10.1016/j.ymgme.2004.09.009 source
- Partly supportedcites [37] Concolino P, Mello E, Minucci A, Giardina E, Zuppi C, Toscano V, Capoluongo E (2009) A new CYP21A1P/CYP21A2 chimeric gene identified in an Italian woman suffering from classical congenital adrenal hyperplasia form. Bmc Med Genet 10:72. https://doi.org/10.1186/1471-2350-10-72 sourceExperimental — accuracy not yet measured
The Discussion reports a woman with salt-wasting CAH and attributes her severe phenotype to homozygosity for an intron-2 splice mutation. It identifies her chimera as CYP21A1P/CYP21A2 CH-6, not TNXA/TNXB CAH-X CH-1, and does not establish that patients with the claimed compound-heterozygous combination generally have the most severe phenotype. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [38] L’Allemand D, Tardy V, Gruters A, Schnabel D, Krude H, Morel Y (2000) How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 85(12):4562–4567. https://doi.org/10.1210/jcem.85.12.7018 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It has been reported that heterozygous TNXB mutations may be associated with the mild joint hypermobility form of EDS [1, 15] and that up to 10% of classic SW-CAH patients harboring in compound heterozygosity a TNXB/CYP21A2 genotype tend to demonstrate an extended phenotype termed CAH-X syndrome [1, 31, 32] (Fig. 2).”
§ Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene > Introduction Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders that affect cortisol biosynthesis and cause defective steroidogenesis [1]. The most prevalent type of CAH is 21-hydroxylase (21-OH) (90–95% of cases), followed by the next most common type of 11β-hydroxylase (11β-OH) (∼ 5% of cases) and other infrequent types [2]. The disorder has a wide spectrum of clinical phenotypes, and severity depends on the patients’ underlying CYP21A2 genotype [1, 3, 4]. Currently, based on the inherited genetic background, the disorder is classified into the “classic” and “non-classic” (NC late onset) CAH forms [1, 2]. In “classic CAH,” during the course of fetal development, the adrenal cannot sufficiently produce cortisol and overproduces androgens, leading to varying degrees of prenatal virilization of the external genitalia in affected girls [5]. The multiallelic and tandem RCCX copy number variation (CNV) locus is found on chromosome 6p23.1 within the major histocompatibility complex (MHC) class III region. The RCCX structure is characteristically defined by the copy number of a DNA segment containing a series of genes, namely, serine/threonine kinase 19 (STK19), complement 4 (C4), steroid 21-OH (CYP21A2), and tenascin-X (TNX). The most frequent RCCX haplotype (69%) comprises two segments that are situated close to each other, with the first one containing the pseudogenes STK19-C4A-CYP21A1P-TNXA and the second containing the genes STK19B-C4B-CYP21A2-TNXB [6]. The majority of deleterious variants, including about 75% of those reported in 21-OH deficiency cases, are transferred to the CYP21A2 gene by small conversions from the CYP21A1P pseudogene during meiosis [6–8]. It is estimated that the remaining 20–30% of the common CYP21A2 pathogenic variants in CAH cases involve large gene deletions or amplifications of the CYP21A2 gene and the other contiguous genes. The formation of these mutants is the result of misalignments due to unequal crossing over during meiosis [6, 9–11]. To date, nine different haplotypes of chimeric CYP21A1P/CYP21A2 genes (CH-1 to CH-9) in 21-OH deficiency have been detected [6, 12, 13]. Likewise, so far, three other chimeric recombination events between the TNXB/TNXA have been reported, which result in the deletion of the CYP21A2 gene, thus creating a CAH disease-causing allele [14, 15]. These three types of TNXB/TNXA chimeras disrupt both the CYP21A2 and the TNXB genes and, according to the type of disruption, have been termed CAH-X CH-1, CH-2, and CH-3 [15]. Approximately 10% of patients with CAH have CAH-X syndrome due to the presence of a monoallelic nonfunctional TNXB/TNXA chimeric gene in combination with another CYP21A2 pathogenic mutation in the second allele [2]. The clinical phenotype of CAH-X includes joint hypermobility, arthralgias, joint dislocations, hernias, and cardiac malformations [2, 15]. The TNXB gene encodes for the large extracellular matrix glycoprotein tenascin-X (TNX) and has a significant structural function in the assembly of collagen deposition by dermal fibroblasts and the connective tissues of the heart and skeletal muscle [16]. Ehlers-Danlos syndrome (EDS), characterized by two autosomal recessive mutations in the TNXB gene, leads to complete deficiency of tenascin-X: patients typically have the classical hypermobile type of EDS, with a characteristically large range of joint movements [17, 18]. Interestingly, there have also been reports of heterozygous TNXB gene mutations causing tenascin-X haploinsufficiency, which also results in the signs and symptoms of hypermobile-type EDS [14, 19, 20]. In recent years, numerous studies have established a robust correlation between the genotype and the phenotype of CAH of a large number of CYP21A2 defects [1–4, 21–27]. In this study, we present the genetic features of the disease in a family of Cypriot descent with the salt-wasting (SW) classic form as a result of the TNXA/TNXB chimera, resulting in deletions of CYP21A2 and TNXB in one allele [7, 15] and a severe case of CYP21A2 mutation in the second allele. > Case description
What the sources say
- Partly supportedcites [1] Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, Fluck CE, Guasti L, Huebner A, Kortmann BBM, Krone N, Merke DP, Miller WL, Nordenstrom A, Reisch N, Sandberg DE, Stikkelbroeck N, Touraine P, Utari A, Wudy SA, White PC (2022) Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev 43(1):91–159. https://doi.org/10.1210/endrev/bnab016 sourceExperimental — accuracy not yet measured
The Molecular genetics of CAH section says that 7–14% of patients with CAH have heterozygous TNXB mutations and calls this extended phenotype CAH-X syndrome. It does not give an estimate specifically for classic salt-wasting CAH patients or describe that group as having the stated compound-heterozygous TNXB/CYP21A2 genotype. The separate discussion of compound heterozygosity in Table 7 concerns CYP21A2 mutations generally. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [31] Burch GH, Gong Y, Liu W, Dettman RW, Curry CJ, Smith L, Miller WL, Bristow J (1997) Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 17(1):104–108. https://doi.org/10.1038/ng0997-104 source
- Not checked — no full text of the sourcecites [32] Gao Y, Lu L, Yu B, Mao J, Wang X, Nie M, Wu X (2020) The prevalence of the chimeric TNXA/TNXB gene and clinical symptoms of Ehlers-Danlos syndrome with 21-hydroxylase deficiency. J Clin Endocrinol Metab 105(7):2288. https://doi.org/10.1210/clinem/dgaa199 source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The TNXA/TNXB chimera results from an infrequent breakpoint of the TNXB gene, leading to complete deletion of C4B and CYP21A2 [15, 30].”
§ Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene > Introduction Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders that affect cortisol biosynthesis and cause defective steroidogenesis [1]. The most prevalent type of CAH is 21-hydroxylase (21-OH) (90–95% of cases), followed by the next most common type of 11β-hydroxylase (11β-OH) (∼ 5% of cases) and other infrequent types [2]. The disorder has a wide spectrum of clinical phenotypes, and severity depends on the patients’ underlying CYP21A2 genotype [1, 3, 4]. Currently, based on the inherited genetic background, the disorder is classified into the “classic” and “non-classic” (NC late onset) CAH forms [1, 2]. In “classic CAH,” during the course of fetal development, the adrenal cannot sufficiently produce cortisol and overproduces androgens, leading to varying degrees of prenatal virilization of the external genitalia in affected girls [5]. The multiallelic and tandem RCCX copy number variation (CNV) locus is found on chromosome 6p23.1 within the major histocompatibility complex (MHC) class III region. The RCCX structure is characteristically defined by the copy number of a DNA segment containing a series of genes, namely, serine/threonine kinase 19 (STK19), complement 4 (C4), steroid 21-OH (CYP21A2), and tenascin-X (TNX). The most frequent RCCX haplotype (69%) comprises two segments that are situated close to each other, with the first one containing the pseudogenes STK19-C4A-CYP21A1P-TNXA and the second containing the genes STK19B-C4B-CYP21A2-TNXB [6]. The majority of deleterious variants, including about 75% of those reported in 21-OH deficiency cases, are transferred to the CYP21A2 gene by small conversions from the CYP21A1P pseudogene during meiosis [6–8]. It is estimated that the remaining 20–30% of the common CYP21A2 pathogenic variants in CAH cases involve large gene deletions or amplifications of the CYP21A2 gene and the other contiguous genes. The formation of these mutants is the result of misalignments due to unequal crossing over during meiosis [6, 9–11]. To date, nine different haplotypes of chimeric CYP21A1P/CYP21A2 genes (CH-1 to CH-9) in 21-OH deficiency have been detected [6, 12, 13]. Likewise, so far, three other chimeric recombination events between the TNXB/TNXA have been reported, which result in the deletion of the CYP21A2 gene, thus creating a CAH disease-causing allele [14, 15]. These three types of TNXB/TNXA chimeras disrupt both the CYP21A2 and the TNXB genes and, according to the type of disruption, have been termed CAH-X CH-1, CH-2, and CH-3 [15]. Approximately 10% of patients with CAH have CAH-X syndrome due to the presence of a monoallelic nonfunctional TNXB/TNXA chimeric gene in combination with another CYP21A2 pathogenic mutation in the second allele [2]. The clinical phenotype of CAH-X includes joint hypermobility, arthralgias, joint dislocations, hernias, and cardiac malformations [2, 15]. The TNXB gene encodes for the large extracellular matrix glycoprotein tenascin-X (TNX) and has a significant structural function in the assembly of collagen deposition by dermal fibroblasts and the connective tissues of the heart and skeletal muscle [16]. Ehlers-Danlos syndrome (EDS), characterized by two autosomal recessive mutations in the TNXB gene, leads to complete deficiency of tenascin-X: patients typically have the classical hypermobile type of EDS, with a characteristically large range of joint movements [17, 18]. Interestingly, there have also been reports of heterozygous TNXB gene mutations causing tenascin-X haploinsufficiency, which also results in the signs and symptoms of hypermobile-type EDS [14, 19, 20]. In recent years, numerous studies have established a robust correlation between the genotype and the phenotype of CAH of a large number of CYP21A2 defects [1–4, 21–27]. In this study, we present the genetic features of the disease in a family of Cypriot descent with the salt-wasting (SW) classic form as a result of the TNXA/TNXB chimera, resulting in deletions of CYP21A2 and TNXB in one allele [7, 15] and a severe case of CYP21A2 mutation in the second allele. > Case description
What the sources say
- Partly supportedcites [15] Miller WL, Merke DP (2018) Tenascin-X, Congenital adrenal hyperplasia, and the CAH-X syndrome. Horm Res Paediatr 89(5):352–361. https://doi.org/10.1159/000481911 sourceExperimental — accuracy not yet measured
The CAH-X section (page unavailable) says that recombination between TNXA and TNXB forms a chimera and deletes CYP21A2. It does not describe the breakpoint as infrequent or say that this event completely deletes C4B. (LLM, conf=0.87)
- Partly supportedcites [30] Blanchong CA, Zhou B, Rupert KL, Chung EK, Jones KN, Sotos JF, Zipf WB, Rennebohm RM, Yung YuC (2000) Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease. J Exp Med 191(12):2183–2196 sourceExperimental — accuracy not yet measured
The Results section (‘Patterns of RCCX Variations in Selected Individuals’; page unavailable) describes a chromosome with deletion of C4B and CYP21B, the functional gene now called CYP21A2. It does not identify that deletion as a TNXA/TNXB chimera or attribute it to an infrequent breakpoint in TNXB. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“CAH-X syndrome is estimated to be found in approximately 7–9% of CAH patients [7, 14, 34] and is classified into three types (CAH-X CH-1, CAH-X CH-2, and CAH-X CH-3) as a result of chimeric recombination events between the TNXB/TNXA during meiosis, resulting in the deletion of the CYP21A2 gene [15].”
§ Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene > Discussion CAH-X syndrome is estimated to be found in approximately 7–9% of CAH patients [7, 14, 34] and is classified into three types (CAH-X CH-1, CAH-X CH-2, and CAH-X CH-3) as a result of chimeric recombination events between the TNXB/TNXA during meiosis, resulting in the deletion of the CYP21A2 gene [15]. The CAH-X CH-1 type is the most frequent of the three and retains a 120-bp deletion at the boundary of exon 35 and intron 35 of TNXB. CAH-X CH-2 and CAH-X CH-3 types are less frequently found in CAH patients, with CAH-X CH-2 being characterized by the variant c.12174C > G (p.Cys4058Trp), which derives from the TNXA pseudogene [7], and CAH-X CH-3, being characterized by a cluster of three mutations (p.Arg4073His, p.Asp4172Asn, and p.Ser4175Asn) also derived from the TNXA pseudogene [35]. CAH-X CH-1 does not produce structural changes in the TNX protein but, rather, reduces the TNX expression, this being in contrast to the altered production of TNX proteins from both CAH-X CH-2 and CAH-X CH-3 [35]. An in-depth molecular genetic approach for the correct diagnosis of the severe forms of CAH, including CAH-X syndrome, is absolutely essential and indeed makes a difference to the everyday practice of an experienced endocrinologist. Lately, in addition to Sanger analysis, which still remains the gold standard for the detection of CYP21A2 gene mutations, the PCR-based techniques of MLPA and real-time PCR assays are widely used for the detection of the severe deletions or duplications. Therefore, in the endocrinologist’s everyday practice, genetic information obtained by using these techniques aids towards taking the most appropriate decisions in cases of prenatal and preimplantation genetic diagnosis, hormonal treatment, and genetic counseling. The female neonate with the classic SW-CAH of the present study presented the highest degree of virilization, with an external genital appearance of Prader 5, and, when salt supplementation was stopped at the age of 4 months, she underwent surgery for the correction of the appearance of her genitalia where a vaginal opening was formed. Similarly to the neonate of the present study, CAH patients that carry in compound heterozygosity the splice IVS2-13A/C > G with the TNXA/TNXB (CAH-X CH-1) chimera generally have the most severe SW phenotype [36–38]. Several reports in European, Mediterranean, Middle Eastern, and Chinese populations confirmed a high frequency of the pathogenic IVS2-13A/C > G and found it to comprise 20 to 25% of the CYP21A2 mutant alleles and to translate to the most severe SW forms of the disease when inherited in homozygosity [1, 4, 27, 39–43]. Since the first CAH-X syndrome report by Merke et al. [14], it has been established that only 10% of CAH-X patients also have EDS manifestations [15, 44]. Several other studies that followed have reported an incidence of IVS2-13A/C > G combined with the chimeric TNXA/TNXB (CAH-X CH-1) genotype in patients with 21-OH deficiency and with no EDS manifestations [32, 44]. Similarly, the neonate of the present case with a compound heterozygous IVS2-13A/C > G/CAH-X CH-1 genotype presented only SW 21-hyroxylase deficiency and no EDS-related clinical manifestations. More specifically, our case has normal skin when compared to certain patients with biallelic CAH-X genotype and who typically demonstrate skin laxity and abnormal wound healing [45, 46]. The father of the neonate who was a carrier of the chimeric TNXA/TNXB (CAH-X CH-1) genotype also did not present any clinical manifestations of EDS. In conclusion, we herein report an infrequent case of CAH illustrating that its clinical phenotype depends on the severity of the underlying variants, while the role of the complex RCCX CNV structure in the development of the disease is explained. Our report moreover constitutes an example of the complexities encountered in patients with classic CAH and adds to the understanding of the spectrum of CAH phenotype and the TNX-related disorders, including the CAH-X syndrome.
What the sources say
- Supportedcites [15] Miller WL, Merke DP (2018) Tenascin-X, Congenital adrenal hyperplasia, and the CAH-X syndrome. Horm Res Paediatr 89(5):352–361. https://doi.org/10.1159/000481911 source
The CAH-X section explains that duplicated genes can misalign during meiosis, that TNXA/TNXB chimeric recombination deletes CYP21A2, and that the resulting chimeras include CAH-X CH-1, CH-2, and CH-3. It states that three such chimeras had been identified at the time of publication. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
12 more claims · 3 with their cited sources checked
Create a free account to see all 35 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 9
Citations
Cites
Speiser, P. W., Dupont, J., Zhu, D., Serrat, J., Buegeleisen, M., Tusie-Luna, M. T., Lesser, M., New, M. I., & White, P. C. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115897 · Cited by 572
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency
Schalkwijk, J., Zweers, M. C., Steijlen, P. M., Dean, W. B., Taylor, G., van Vlijmen, I. M., van Haren, B., Miller, W. L., & Bristow, J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002939 · Cited by 391 · cited 1×
“More specifically, our case has normal skin when compared to certain patients with biallelic CAH-X genotype and who typically demonstrate skin laxity and abnormal wound healing [45, 46].”
ResultWedell, A. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.5.1145 · Cited by 370 · cited 1×
“In “classic CAH,” during the course of fetal development, the adrenal cannot sufficiently produce cortisol and overproduces androgens, leading to varying degrees of prenatal virilization of the external genitalia in affected girls [5].”
BackgroundTenascin-X deficiency is associated with Ehlers-Danlos syndrome
Burch, G. H., Gong, Y., Liu, W., Dettman, R. W., Curry, C. J., Smith, L., Miller, W. L., & Bristow, J. (1997) · Nature Genetics · doi:10.1038/ng0997-104 · Cited by 366 · cited 9×
“The father of the neonate who was a carrier of the chimeric TNXA/TNXB (CAH-X CH-1) genotype also did not present any clinical manifestations of EDS.”
BackgroundInfluentialNew, M. I., Abraham, M., Gonzalez, B., Dumic, M., Razzaghy-Azar, M., Chitayat, D., Sun, L., Zaidi, M., Wilson, R. C., & Yuen, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300057110 · Cited by 365
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B
Bristow, J., Tee, M., Gitelman, S., Mellon, S., & Miller, W. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.265 · Cited by 302 · cited 1×
“The TNXB gene encodes for the large extracellular matrix glycoprotein tenascin-X (TNX) and has a significant structural function in the assembly of collagen deposition by dermal fibroblasts and the connective tissues of the heart and skeletal muscle [16].”
BackgroundHaploinsufficiency of TNXB Is Associated with Hypermobility Type of Ehlers-Danlos Syndrome
Zweers, M. C., Bristow, J., Steijlen, P. M., Dean, W. B., Hamel, B. C., Otero, M., Kucharekova, M., Boezeman, J. B., & Schalkwijk, J. (2003) · The American Journal of Human Genetics · doi:10.1086/376564 · Cited by 242 · cited 9×
“The father of the neonate who was a carrier of the chimeric TNXA/TNXB (CAH-X CH-1) genotype also did not present any clinical manifestations of EDS.”
BackgroundInfluentialFinkielstain, G. P., Chen, W., Mehta, S. P., Fujimura, F. K., Hanna, R. M., Van Ryzin, C., McDonnell, N. B., & Merke, D. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0319 · Cited by 192
Cited by
Fanis, P., Skordis, N., Toumba, M., Picolos, M. K., Tanteles, G. A., Neocleous, V., & Phylactou, L. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156616 · Cited by 8
Self-citationCOVID-19, diabetes mellitus type 2, endocrine genetics, and pituitary and adrenal diseases
Stratakis, C. A. (2023) · HORMONES · doi:10.1007/s42000-023-00436-8 · Cited by 3
Neocleous, V., Fanis, P., Toumba, M., Skordis, N., & Phylactou, L. A. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03171-4 · Cited by 1
Self-citationTrastorno de diferenciación sexual por hiperplasia suprarrenal congénita. Reporte de un caso
Jara, D. T. B., & Quizhpi-Paredes, D. E. (2023) · Salud ConCiencia · doi:10.55204/scc.v2i2.e48
“Desde el punto de vista clínico, esta condición se divide en dos categorías: la forma clásica, que se caracteriza por la pérdida de sal y una virilización simple; y la forma no clásica, que se presenta de https://doi.org/10.55204/scc.v2i2.e48 manera sintomática y, a menudo, de forma más oculta (13).”
BackgroundInfluential
Metadata
- Authors
- Fanis, P., Skordis, N., Phylactou, L. A., & Neocleous, V.
- Affiliations
- Cyprus Institute of Neurology and Genetics (CY)
- University of Nicosia (CY)
- Corresponding author
- Phylactou, Leonidas A.
- Venue
- HORMONES
- Published
- 2022-10-20
- Volume
- 22
- Issue
- 1
- Pages
- 71-77
- ISSN
- 1109-3099 (ISSN-L)
- 2520-8721
- PMC
- PMC10011304
- OpenAlex
- W4306912920
- Cited by
- 4
- References
- 47
- Citations by year
- 2024: 1 · 2023: 3
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- HORMONES (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- A.G. Leventis Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- salt-wasting congenital adrenal hyperplasia, CYP21A2, 21-hydroxylase deficiency, compound heterozygosity, homologous recombination, contiguous gene deletion, pseudogenes, genetic counseling, prenatal diagnosis
- MeSH terms
- Adrenal Hyperplasia, Congenital, Female, Humans, Male, Mutation, Phenotype, Steroid 21-Hydroxylase, Tenascin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene. https://app.cochat.ai/papers/10.1007/s42000-022-00410-w
- The paper
- Fanis, P., Skordis, N., Phylactou, L. A., & Neocleous, V. (2023). Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene. HORMONES. https://doi.org/10.1007/s42000-022-00410-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.